Royalty Pharma (NASDAQ:RPRX) Upgraded by StockNews.com to Buy

Royalty Pharma (NASDAQ:RPRX) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Friday.

RPRX has been the subject of several other reports. The Goldman Sachs Group increased their target price on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target for the company. in a research report on Monday, June 3rd. Finally, Morgan Stanley raised their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Royalty Pharma has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $29.13 on Friday. The company has a 50-day moving average price of $27.29 and a 200 day moving average price of $28.21. Royalty Pharma has a 52 week low of $25.20 and a 52 week high of $31.66. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The company has a market cap of $17.40 billion, a P/E ratio of 21.74, a PEG ratio of 4.01 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The business had revenue of $537.00 million during the quarter, compared to analysts’ expectations of $600.83 million. During the same period last year, the company posted $0.85 EPS. Research analysts predict that Royalty Pharma will post 4.04 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Swedbank AB acquired a new stake in shares of Royalty Pharma during the first quarter valued at about $251,461,000. Norges Bank purchased a new position in shares of Royalty Pharma during the fourth quarter valued at approximately $119,740,000. New South Capital Management Inc. purchased a new position in shares of Royalty Pharma during the first quarter valued at approximately $44,384,000. ADAR1 Capital Management LLC purchased a new position in Royalty Pharma in the fourth quarter worth $37,130,000. Finally, Patient Capital Management LLC bought a new stake in shares of Royalty Pharma in the fourth quarter valued at $35,247,000. Institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.